XML 66 R56.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaboration and License Agreements - Bristol-Myers Squibb Company - Additional Information (Details) $ in Thousands |  |  | 1 Months Ended | 12 Months Ended |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 25, 2017 USD ($) Target | Jul. 07, 2014 USD ($) Target Term | Mar. 31, 2020 USD ($) | Jan. 31, 2018 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Feb. 29, 2020 USD ($) | Nov. 30, 2017 USD ($) | Mar. 17, 2017 Target | Dec. 31, 2016 USD ($) | Jan. 31, 2016 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | $ 94,063 | $ 212,315 | $ 301,326 |  |  |  |  |
Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | $ 41,900 |  |  |  |  |  |  |
Collaborative Arrangement | Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Collaboration target research term |  | 2 years |  |  |  |  |  |  |  |  |  |
Number of additional collaboration target | Target |  | 2 |  |  |  |  |  |  |  |  |  |
Research terms |  |  |  |  | Each collaboration target had a two-year research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times. |  |  |  |  |  |  |
Extension of research term for each collaboration target |  | 1 year |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 200,000 | $ 50,000 |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable |  |  |  |  | $ 1,300,000 |  |  | $ 10,000 |  |  | $ 15,000 | $ 10,000
Number of research targets selected | Target | 8 |  |  |  |  |  |  |  |  |  |  |
Total transaction price |  | 304,700 |  |  |  |  |  |  |  |  |  |
Upfront fee received |  | 250,000 |  |  |  |  |  |  |  |  |  |
Research and development service fees |  | 17,700 |  |  |  |  |  |  |  |  |  |
Milestone payment received |  |  | $ 10,000 | $ 12,000 |  |  |  |  |  |  |  |
Milestone payments received |  |  |  |  | 297,000 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | $ 41,900 | $ 119,900 |  |  |  |  |  |
Collaborative Arrangement | Bristol Myers Squibb | Pre Clinical Candidate |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable |  |  |  |  |  |  |  |  |  |  | $ 2,000 |
Collaborative Arrangement | Bristol Myers Squibb | Third And Fourth Target |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Target selection fee |  | $ 25,000 |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement | Bristol Myers Squibb | New Drug Application for CTLA-4 |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable |  |  |  |  |  |  |  |  | $ 10,000 |  |  |
Collaborative Arrangement | Maximum | Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of oncology target | Target |  | 4 |  |  |  |  |  |  |  |  |  |
Number of collaboration target | Target |  | 2 |  |  |  |  |  |  |  |  |  |
Period of nomination of additional target from effective date |  | 5 years |  |  |  |  |  |  |  |  |  |
Times of increments for extended collaboration target research time | Term |  | 3 |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement | Maximum | Bristol Myers Squibb | Each Of Two Additional Targets |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable |  | $ 25,000 |  |  |  |  |  |  |  |  |  |
Collaboration and License Agreement | Maximum | Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of additional collaboration target | Target |  |  |  |  |  |  |  |  |  | 8 |  |

X
- Definition Aggregate collaboration transaction amount. + References No definition available. + Details
Name: | ctmx_AggregateCollaborationTransactionAmount
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration target research term. + References No definition available. + Details
Name: | ctmx_CollaborationTargetResearchTerm
Namespace Prefix: | ctmx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future contingent milestone payment receivable. + References No definition available. + Details
Name: | ctmx_ContingentMilestonePaymentsReceivable
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Extension of research term for each collaboration target. + References No definition available. + Details
Name: | ctmx_ExtensionOfResearchTermForEachCollaborationTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increments of extended collaboration target research times. + References No definition available. + Details
Name: | ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Milestone payment received. + References No definition available. + Details
Name: | ctmx_MilestonePaymentReceived
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments received from revenue recognized during period. + References No definition available. + Details
Name: | ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of additional collaboration target. + References No definition available. + Details
Name: | ctmx_NumberOfAdditionalCollaborationTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of collaboration target. + References No definition available. + Details
Name: | ctmx_NumberOfCollaborationTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of oncology target. + References No definition available. + Details
Name: | ctmx_NumberOfOncologyTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of research targets selected. + References No definition available. + Details
Name: | ctmx_NumberOfResearchTargetsSelected
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period of nomination of additional target. + References No definition available. + Details
Name: | ctmx_PeriodOfNominationOfAdditionalTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and development service fees. + References No definition available. + Details
Name: | ctmx_ResearchAndDevelopmentServiceFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Target selection fees. + References No definition available. + Details
Name: | ctmx_TargetSelectionFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront fee received. + References No definition available. + Details
Name: | ctmx_UpfrontFeeReceived
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ctmx_PreClinicalCandidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ctmx_ThirdAndFourthTargetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ctmx_DrugApplicationForCTLA4Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=ctmx_AchievingAdditionalTargetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |